Natera director Jonathan Sheena sells $603,710 in company stock

Jonathan Sheena, a director and co-founder of Natera, Inc. (NASDAQ:NTRA), disposed of common stock totaling approximately $603,710 on October 16, 2026. The shares were sold at prices ranging between $398.9536 and $409.3575.

The transactions involved the sale of 1,580 shares of Natera common stock. These sales were carried out under a Rule 10b5-1 trading plan, which Mr. Sheena adopted on June 11, 2026. The shares were held indirectly for the benefit of beneficiaries of the Caraluna 1 Trust and Caraluna 2 Trust, with Mr. Sheena disclaiming beneficial ownership over these securities.The sale comes as Natera stock trades near its 52-week high of $437.41, following a remarkable 117% return over the past year. According to InvestingPro analysis, the stock currently appears overvalued relative to its Fair Value, placing it among the most overvalued stocks in the market. The company, valued at $58.5 billion, has 13 additional ProTips available to subscribers.

Following these transactions, Mr. Sheena directly owns 221,314 shares of Natera common stock, and indirectly holds 8,250 shares through each of the Caraluna 1 Trust and Caraluna 2 Trust.

In other recent news, Natera reported second-quarter revenue significantly surpassing Wall Street expectations, with figures reaching approximately $753 million compared to the anticipated $661.26 million. This performance was bolstered by accelerated growth across its main businesses, leading the company to raise its full-year revenue guidance. Additionally, Natera highlighted record test volume, improved margins, and a series of regulatory wins as contributing factors to its strong financial results.

In terms of analyst activity, RBC Capital increased its price target for Natera to $460, maintaining an Outperform rating. This decision was based on the company’s promising growth prospects in the minimal residual disease (MRD) testing market, where Natera holds a dominant position. Similarly, Rothschild Redburn initiated coverage of Natera with a Buy rating, setting a price target of $385. The firm emphasized Natera’s leadership in MRD testing, particularly with its Signatera tumor-informed test and other developments in cancer detection. These recent developments reflect a positive outlook from analysts regarding Natera’s market position and future potential.